Therapeutically relevant engraftment of a CRISPR-Cas9-edited HSC-enriched population with HbF reactivation in nonhuman primates
Humbert, Olivier, Radtke, Stefan, Samuelson, Clare, Carrillo, Ray R, Perez, Anai M, Reddy, Sowmya S, Lux, Christopher, Pattabhi, Sowmya, Schefter, Lauren E, Negre, Olivier, Lee, Ciaran M, Bao, Gang, Adair, Jennifer E, Peterson, Christopher W, Rawlings, David J, Scharenberg, Andrew M, Kiem, Hans-Peter
Published in Science translational medicine (31.07.2019)
Published in Science translational medicine (31.07.2019)
Get more information
Journal Article
Engineering resistance to CD33-targeted immunotherapy in normal hematopoiesis by CRISPR/Cas9-deletion of CD33 exon 2
Humbert, Olivier, Laszlo, George S, Sichel, Sophie, Ironside, Christina, Haworth, Kevin G, Bates, Olivia M, Beddoe, Mary E, Carrillo, Ray R, Kiem, Hans-Peter, Walter, Roland B
Published in Leukemia (01.03.2019)
Published in Leukemia (01.03.2019)
Get full text
Journal Article
712 SBT6290, a systemically administered Nectin-4-directed TLR8 ImmunoTAC (TM) therapeutic, is a potent human myeloid cell agonist for the treatment of Nectin-4-expressing tumors
Metz, Heather, Brender, Ty, Stevens, Brenda, Winship, Damion, Brevik, Jamie, Comeau, Michael, Childs, Monica, Chang, Jenny, Fan, Li-Qun, Xu, Hengyu, Grey, Jonathan, Adamo, Jeffrey, Setter, Ben, Carrillo, Ray, Smith, Sean, Tan, Phil, DuBose, Robert, Latchman, Yvette, Baum, Peter, Odegard, Valerie
Published in Journal for immunotherapy of cancer (01.11.2020)
Published in Journal for immunotherapy of cancer (01.11.2020)
Get full text
Journal Article